ticagrelor_enfermedad_vascular_periférica

Back to Basics: Ticagrelor Questioned and Clopidogrel in the Limelight

Yet another observational study has come to question the antiaggregation power of ticagrelor when it comes to death or MI reduction, pointing at its higher risk of bleeding vs. clopidogrel.  This new analysis recently published in JAHA includes a large number of patients undergoing acute coronary syndrome (ACS) in the clinical practice.  Ticagrelor has been<a href="https://solaci.org/en/2021/04/28/back-to-basics-ticagrelor-questioned-and-clopidogrel-in-the-limelight/" title="Read more" >...</a>

Xience Receives CE Mark for Short and Ultrashort DAPT Schemes

Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients with high risk of bleeding.   The CE Mark approval comes after studies Xience 28 and Xience 90 are published. Immediately after authorization, Abbot was fast to announce what they consider to be the shortest approved scheme with the most<a href="https://solaci.org/en/2021/04/26/xience-receives-ce-mark-for-short-and-ultrashort-dapt-schemes/" title="Read more" >...</a>

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

More Evidence for Short Term DAPT: Approaching “the Class Effect”

Patients at high risk of bleeding undergoing coronary angioplasty with Orsiro stent can be considered for a short dual antiplatelet scheme.  These data come from the SMART-CHOICE study recently published in JAHA, adding the Orsiro stent to the list of devices supporting 3-month DAPT.  This study included 2993 patients undergoing coronary angioplasty randomized to 3<a href="https://solaci.org/en/2021/01/27/more-evidence-for-short-term-dapt-approaching-the-class-effect/" title="Read more" >...</a>

The most relevant articles in pharmacology in 2020

In this selection, we summarize for you the most important scientific news of 2020 in the field of pharmacology. 01- Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to the COLCOT trial, originally presented at the<a href="https://solaci.org/en/2020/12/17/the-most-relevant-articles-in-pharmacology-in-2020/" title="Read more" >...</a>

The Most Read Scientific Articles in Interventional Cardiology

01- How To De-Escalate Prasugrel After Acute Coronary Syndrome? Patients who undergo coronary angioplasty after acute coronary syndrome could de-escalate dual antiplatelet therapy with prasugrel to maintain the protection against ischemic events while lowering their hemorrhagic risk. Read more HERE 02- Not All Coronary Spasms Are the Same: Benefits of Acetylcholine Patients with documented spasm<a href="https://solaci.org/en/2020/11/17/the-most-read-scientific-articles-in-interventional-cardiology-2/" title="Read more" >...</a>

Aspirina o clopidogrel post TAVI: Guías y estudios llenos de contradicciones

Angioplasty in Aspirin-Free Stable Patients with Prasugrel: Innovation Continues

Potent P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, have been tested mainly in a setting of acute coronary syndromes. There is little evidence on stable patients, particularly for prasugrel. Designing a study with that purpose seemed challenging enough, but adding aspirin discontinuation in patients without a particularly high bleeding risk took this research to<a href="https://solaci.org/en/2020/11/10/angioplasty-in-aspirin-free-stable-patients-with-prasugrel-innovation-continues/" title="Read more" >...</a>

The Ten Commandments from the New Guidelines on Infarction Without ST-Segment Elevation

In 2020, the European Society of Cardiology guidelines for the management of patients with acute coronary syndromes without ST-segment elevation (Non-ST-Segment Elevation Myocardial Infarction, NSTEMI) were presented. This document went somewhat unnoticed in the context of the COVID-19 pandemic, so this seems a good time to review it and set out some practical “commandments” (something<a href="https://solaci.org/en/2020/11/05/the-ten-commandments-from-the-new-guidelines-on-infarction-without-st-segment-elevation/" title="Read more" >...</a>

How To De-Escalate Prasugrel After Acute Coronary Syndrome?

Patients who undergo coronary angioplasty after acute coronary syndrome could de-escalate dual antiplatelet therapy with prasugrel to maintain the protection against ischemic events while lowering their hemorrhagic risk. The HOST-REDUCE-POLYTECH-ACS study (recently published in The Lancet) included 2338 patients who underwent coronary angioplasty in a setting of acute coronary syndrome. Patients were randomized to a year-long<a href="https://solaci.org/en/2020/10/21/how-to-de-escalate-prasugrel-after-acute-coronary-syndrome/" title="Read more" >...</a>

Can Aspirin Use Be Interrupted After Angioplasty?

Aspirin discontinuation 1 to 3 months after angioplasty with continued P2Y12 inhibitor therapy reduces the bleeding risk without an increase in thrombotic events. This is also the case for patients admitted with acute coronary syndrome. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to reduce the risk of major events compared with<a href="https://solaci.org/en/2020/09/01/can-aspirin-use-be-interrupted-after-angioplasty/" title="Read more" >...</a>

Es posible esterilizar las máscaras N95 y los barbijos quirúrgicos

Thrombosis and Thromboembolism Associated with COVID-19

Coronavirus disease 2019 (COVID-19) is a viral respiratory illness that can cause a severe acute respiratory syndrome (SARS-CoV-2), predisposing patients to thrombosis (both in veins and arteries) due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for different indications may now become infected with COVID-19, which can<a href="https://solaci.org/en/2020/05/13/thrombosis-and-thromboembolism-associated-with-covid-19/" title="Read more" >...</a>